The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
 
 
Consulting or Advisory Role - Abbvie; AMOMED Pharma GmbH; Celgene/Bristol-Myers Squibb; Karyopharm Therapeutics; Novartis; ROCHE; Sandoz; Sierra Oncology; Sumitomo Dainippon Pharma Oncology
Speakers' Bureau - Abbvie; AOP Orphan Pharmaceuticals; Celgene/Bristol-Myers Squibb; Novartis
Safety and efficacy of luspatercept for the treatment of anemia in patients with myelofibrosis: Results from the ACE-536-MF-001 study.
 
Aaron Thomas Gerds
Consulting or Advisory Role - Abbvie; Constellation Pharmaceuticals; CTI BioPharma Corp; GlaxoSmithKline/Sierra Oncology; Incyte; Kartos Therapeutics; Novartis; PharmaEssentia
Research Funding - Celgene/Bristol-Myers Squibb
 
Claire Harrison
Honoraria - Abbvie; CTI BioPharma Corp; Geron; Janssen; Novartis
Consulting or Advisory Role - AOP Orphan Pharmaceuticals; Celgene; Constellation Pharmaceuticals; CTI; Galecto; Geron; Gilead Sciences; Janssen; Keros Therapeutics; Novartis; Promedior; Roche; Shire; Sierra Oncology
Speakers' Bureau - Abbvie; Bristol-Myers Squibb; CTI BioPharma Corp; Geron; Novartis; Sierra Oncology
Research Funding - Bristol-Myers Squibb (Inst); Constellation Pharmaceuticals (Inst); Novartis (Inst)
 
Jean-Jacques Kiladjian
Consulting or Advisory Role - Abbvie; AOP Orphan Pharmaceuticals; BMS; Incyte; Novartis; Pharmaessentia
 
Ruben A. Mesa
Consulting or Advisory Role - Constellation Pharmaceuticals; La Jolla Pharma; Novartis; Sierra Oncology
Research Funding - Abbvie (Inst); Celgene (Inst); Constellation Pharmaceuticals (Inst); CTI (Inst); Genentech (Inst); Incyte (Inst); Mays Cancer Center (Inst); NCI (Inst); Promedior (Inst); Samus (Inst)
 
Alessandro M. Vannucchi
Consulting or Advisory Role - Abbvie; AOP Orphan Pharmaceuticals; Blueprint Medicines; Bristol-Myers Squibb; CTI; GlaxoSmithKline; Incyte; Novartis
 
Rami S. Komrokji
Stock and Other Ownership Interests - Abbvie
Consulting or Advisory Role - Abbvie; Bristol-Myers Squibb; CTI BioPharma Corp; Geron; Gilead/Forty Seven; Jazz Pharmaceuticals; Novartis; Pharmaessentia; Taiho Oncology; Takeda
Speakers' Bureau - Abbvie; CTI BioPharma Corp; Jazz Pharmaceuticals; Pharmaessentia; SERVIER
Research Funding - Bristol-Myers Squibb/Celgene (Inst)
Travel, Accommodations, Expenses - Bristol-Myers Squibb; Jazz Pharmaceuticals; Pharmaessentia
 
Prithviraj Bose
Honoraria - Abbvie; Blueprint Medicines; BMS; CTI BioPharma Corp; Incyte; Karyopharm Therapeutics; Novartis; Pharmaessentia
Consulting or Advisory Role - Sierra Oncology
Research Funding - Blueprint Medicines (Inst); Bristol Myers Squibb (Inst); Celgene (Inst); Celgene (Inst); Cogent Biosciences (Inst); Constellation Pharmaceuticals (Inst); CTI BioPharma Corp (Inst); Incyte (Inst); Kartos Therapeutics (Inst); NS Pharma (Inst); Promedior (Inst)
 
Marina Kremyanskaya
Honoraria - Abbvie; Constellation Pharmaceuticals; CTI BioPharma Corp; Incyte; Protagonist Therapeutics
Consulting or Advisory Role - Abbvie; Constellation Pharmaceuticals; CTI BioPharma Corp; incyte (I); Protagonist Therapeutics
 
Adam J. Mead
Stock and Other Ownership Interests - Alethiomics
Honoraria - Abbvie; Celgene/Bristol-Myers Squibb; Constellation Pharmaceuticals; CTI; Karyopharm Therapeutics; Novartis
Research Funding - Alethiomics; Celgene/Bristol-Myers Squibb; Galecto; Novartis
Patents, Royalties, Other Intellectual Property - AJM is co-founder and equity holder in Alethiomics Ltd, a spin out company from the University of Oxford. AJM has licensed a patent to Alethiomics.
 
Jason R. Gotlib
Consulting or Advisory Role - Abbvie
Research Funding - Bristol-Myers Squibb (Inst); Kartos Therapeutics (Inst)
 
Fabian Sanabria
Employment - Bristol-Myers Squibb
 
Niloufar Marsousi
Employment - Bristol-Myers Squibb
 
Ana Carolina Giuseppi
Employment - Bristol-Myers Squibb
 
Huijing Jiang
Employment - Bristol-Myers Squibb
 
Jeanne M. Palmer
Consulting or Advisory Role - MorphoSys
 
Kelly McCaul
Speakers' Bureau - Bristol-Myers Squibb
 
Vincent Ribrag
Honoraria - Abbvie; AZD; Gilead Sciences; Infinity Pharmaceuticals; NanoString Technologies; Novartis; roche
Consulting or Advisory Role - Bristol-Myers Squibb; Gilead Sciences; Immune Design; Incyte; Infinity Pharmaceuticals; MSD; NanoString Technologies; PharmaMar; Roche; Roche/Genentech
Research Funding - arGEN-X BVBA; argenx (Inst); Astex Pharmaceuticals (Inst); Epizyme (Inst); GlaxoSmithKline/Adaptimmune (Inst)
Expert Testimony - SERVIER
Travel, Accommodations, Expenses - azd; AZD; Bristol-Myers Squibb; Bristol-Myers Squibb; Roche
 
Srdan Verstovsek
Consulting or Advisory Role - Celgene; Constellation Pharmaceuticals; Incyte; Novartis; Sierra Oncology
Research Funding - AbbVie (Inst); Celgene (Inst); Constellation Pharmaceuticals (Inst); Galecto (Inst); Geron (Inst); Incyte (Inst); Kartos Therapeutics (Inst); PharmaEssentia (Inst); Protagonist Therapeutics (Inst); Sierra Oncology (Inst); Telios (Inst)
 
Francesco Passamonti
No Relationships to Disclose